Research location
Suita
Osaka, Japan
Advertisement
Research activity in Suita
Osaka, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 144 trials and 155 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Suita
144 linked trials · page 1 of 3A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)NCT07646860 · 2026-09-17 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549 · 2026-06-10 · 1 site observation
RECRUITING
Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart FailureNCT07397650 · 2026-05-11 · 2 site observations
RECRUITING
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.NCT07543120 · 2026-05-07 · 1 site observation
RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NCT06947941 · 2026-03-25 · 1 site observation
RECRUITING
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07179380 · 2026-01-07 · 1 site observation
RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation
RECRUITING
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 2 site observations
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation
RECRUITING
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation
RECRUITING
ELEVATE-HFpEF Clinical StudyNCT06678841 · 2025-07-09 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation
RECRUITING
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsNCT06033950 · 2024-08-20 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart FailureNCT05392764 · 2022-09-10 · 1 site observation
RECRUITING
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)NCT07794761 · 2026-09-28 · 1 site observation
NOT_YET_RECRUITING
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)NCT07794774 · 2026-09-28 · 1 site observation
NOT_YET_RECRUITING
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · 2025-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)NCT06925750 · 2025-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)NCT06664801 · 2024-11-14 · 1 site observation
COMPLETED
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645 · 2024-11-04 · 1 site observation
TERMINATED
A Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisNCT06655896 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324 · 2024-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate CancerNCT06441994 · 2024-05-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 MonotherapyNCT06236061 · 2024-04-08 · 1 site observation
COMPLETED
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentNCT06105632 · 2024-01-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's DiseaseNCT05983575 · 2023-10-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Special Drug Use Surveillance of Entresto Tablets (Hypertension)NCT05976230 · 2023-09-04 · 2 site observations
COMPLETED
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)NCT05818137 · 2023-05-10 · 1 site observation
COMPLETED
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerNCT05654623 · 2023-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Ponsegromab in People With Heart FailureNCT05492500 · 2022-09-26 · 1 site observation
TERMINATED
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSCNCT05495425 · 2022-06-01 · 1 site observation
COMPLETED
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanNCT05399329 · 2022-04-20 · 1 site observation
COMPLETED
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsNCT05013008 · 2021-08-18 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenNCT04940065 · 2021-06-30 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.